Navigation Links
Zucker Hillside Researchers to Receive Large Federal Grant to Test for the Early Treatment of Schizophrenia
Date:7/21/2009

People with schizophrenia have long received an inconsistent mix of treatments depending on where they lived and what doctors they saw. Now, the federal government has announced an innovative study to test the impact of the best available treatments and whether the interventions will reduce future episodes of schizophrenia and help young people get their brains and lives back on track.

Manhasset, NY (Vocus) July 21, 2009 -- People with schizophrenia have long received an inconsistent mix of treatments depending on where they lived and what doctors they saw. Now, the federal government has announced an innovative study to test the impact of the best available treatments and whether the interventions will reduce future episodes of schizophrenia and help young people get their brains and lives back on track.

The study, called RAISE, is a contract funded by the National Institute of Mental Health, the National Institutes of Health and the American Recovery and Reinvestment Act (ARRA). The government will fund $40 million over six years -- of which about half is earmarked for scientists at The Zucker Hillside Hospital campus of The Feinstein Institute for Medical Research. The project will involve two independent teams of researchers, one being led by Zucker Hillside/Feinstein scientists and another at Columbia University’s New York State Psychiatric Institute.

The interventions include the latest pharmacological and psychosocial treatments; the study design includes doctors, patients, families and scientists who will weigh in on the interventions to identify what works and what doesn’t. Once the intervention package is complete, scientists will train doctors and other health professionals throughout the country and then test the treatments in small towns and big cities around the nation where one in every 100 young adults and their families are handed the devastating diagnosis. This brain illness can cause hallucinations, delusions and life-disrupting changes in thought, mood and behavior.

Studies have shown that people with schizophrenia generally do not get appropriate treatments early enough in the course of the disease and this may lead to a more disabling form of the illness. Symptoms generally appear in late adolescence or early adulthood, and can disrupt the normal course of life and derail even the smartest minds.

Traditionally, patients have been given an inconsistent variety of treatments and studies show that most people never make it back to where they were before the symptoms hit. No one really knows how early, consistent, state-of-the-art treatments will affect the course of this illness, and this federal initiative is the first attempt to figure it out. The teams will be led by John Kane, MD, chairman of psychiatry at Zucker Hillside Hospital in Glen Oaks, NY, and Jeffrey Lieberman, MD, of Columbia University. “This is novel because there has never been an attempt to study the impact of carefully integrated modern pharmacologic and psychosocial treatments in first-episode patients,” he said. “This project will give us strategies that may change the course of illness for patients early in the disease process. We have some promising approaches that need to be combined and then tested on individuals in many different kinds of settings.

“We have a sense of what treatments work, but these interventions haven’t been tested in an integrated approach. This study is uniquely designed to answer the question of how best to treat people in the early stages of schizophrenia,” added Dr. Kane, internationally known for his work in the treatment of schizophrenia patients.

Once the interventions are selected and people trained to deliver them in a consistent fashion, 200 newly-diagnosed patients will be identified and enrolled in the study. The scientists will follow the patients over time to see whether their symptoms improve and if their social and vocational functioning get better with the selected interventions. The group will be tested against patients participating in the study and receiving standard psychiatric care in community clinics around the country.

“Can we do a better job helping patients with a more comprehensive treatment package? We definitely think so,” said Dr. Kane. “We hope this study will not only help us to change the course and outcome of schizophrenia, but also to change the way that people think about this brain disease. We hope the study will demonstrate that schizophrenia can be effectively treated and managed so that individuals who experience its onset can have a high likelihood of recovering and doing many of the things that we all take for granted: going to school, working, having hobbies, friends and intimate relationships. We’re very excited about this opportunity.”

“This new initiative will help us determine whether intervention that is started early, incorporates diverse treatment and rehabilitation approaches, and is sustained over time, can make it possible for more people with schizophrenia to return successfully to work and school,” said NIMH Director Thomas R. Insel, M.D. “Moreover, the interventions being tested will be designed from the outset to be readily adopted in real-world health care settings and quickly put into practice.”    

RAISE is a model example of how money from the Recovery Act can accelerate science related to public health problems and potentially benefit those citizens most in need.

For more information on the study: http://www.nimh.nih.gov/health/topics/schizophrenia/raise/index.shtml.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2664634.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Joseph D. Zuckerman, M.D., Elected President of the American Academy of Orthopaedic Surgeons
2. Researchers find that eating high levels of fructose impairs memory in rats
3. Ben-Gurion U. researchers identify how stressed fat tissue malfunctions
4. U of M researchers find childhood cancer risk rises with mothers age
5. Researchers map how staph infections alter immune system
6. Researchers identify individuals at risk for developing colon cancer
7. Arizona researchers to sequence West African rice strain
8. Six Researchers to Receive Prestigious Awards from the American Society of Hematology
9. Mount Sinai researchers find new Alzheimers disease treatment promising
10. Researchers consider herd movements to help eradicate bovine TB
11. Pre-cessation patch doubles quit success rate: Researchers call for labeling changes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Zucker Hillside Researchers to Receive Large Federal Grant to Test for the Early Treatment of Schizophrenia
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
(Date:11/30/2016)... Wisconsin (PRWEB) , ... November 30, 2016 , ... ... in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of the ... year on the list, having ranked from 2008-2016. In addition, Standard Process was ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... and mental health treatment has announced the opening of a new residential mental ... for girls with mental health issues such as severe anxiety, depression, bi-polar disorder, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... stylish design wanted by today’s consumers at an affordable price, is now available ... the new watch is “a game changer” when it comes to the smartwatch. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2016  The Addiction Treatment Advisory Group (ATAG), ... Care Pharmacy (AMCP), has released detailed findings on ... opioid addiction crisis, including through improved access to ... ATAG,s newly released paper, "The Role of Managed ... many issues around gaps and barriers to addiction ...
(Date:12/2/2016)... 2, 2016 Boston Scientific Corporation (NYSE: ... acquire certain manufacturing assets and capabilities of the Neovasc, ... biological tissue business, as well as a 15% equity ... in cash. The Neovasc advanced biological tissue business makes ... Scientific Lotus™ Valve System. * Upon completion of ...
Breaking Medicine Technology: